This CME program will highlight recent advances in disease management of generalized myasthenia gravis (MG). The expert faculty, led by Dr. Vera Bril, will first outline the pathophysiology of myasthenia gravis, detailing epidemiology, pathogenesis and the case for targeted treatments. Following, current clinical trial data for FcRn inhibitors in MG will be analyzed, including a review of mechanisms of action. The faculty will conclude with a discussion of practical considerations for implementing current therapies in clinical practice. Upon completion of this activity, clinicians will be equipped with pertinent data to improve outcomes and quality of life in patients with myasthenia gravis.
MG and other neuromuscular disease specialists, neuroimmunologists, general neurologists, other physicians, specialty and hospital pharmacists, and NPs and PAs who manage patients with MG
I. Pathophysiology of Generalized Myasthenia Gravis and the Rationale for Targeted, Non-Steroidal Immune-Mediated Therapy – Carolina Barnett-Tapia, MD
II. FcRn inhibitors in MG: Mechanism of Action, Clinical Trial Data, Implementation of Therapy –Vera Bril, MD
III. Interactive Panel Discussion – Vera Bril, MD and Carolina Barnett-Tapia, MD
- Understand the pathophysiology of generalized myasthenia gravis and the rationale for targeted, non-steroidal immune-mediated therapy
- Explain the mechanism of action of FcRn and complement inhibitors in MG and review recent clinical trial data
- Plan implementation of therapy with appropriate selection of patients for individualized management of generalized MG by the interprofessional team
Disclosures of Relevant Financial Relationships
It is the policy of AcademicCME that all faculty, instructors, and planners disclose relevant financial relationships relating to the topics of this educational activity. Any relevant financial relationships are mitigated via a content review by planning committee members and faculty with no relevant financial relationships.
The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CE activity:
|Faculty||Relationship Identified With:|
|Vera Bril, MD||Consultant/Advisor: Akcea Therapeutics, Inc.; Alexion Pharmaceuticals, Inc.; Alnylam Pharmaceuticals, Inc.; argenX; AstraZeneca; CSL; F. Hoffmann-La Roche Ltd; Grifols; Immunovant, Inc.; Ionis Pharmaceuticals; Janssen Global Services, LLC; Japan Tobacco; Johnson & Johnson Services, Inc.; Momenta; Novo Nordisk A/S; Octapharma USA, Inc.; Pfizer Inc.; Powell Mansfield Inc.; Sanofi; Takeda Pharmaceutical Company Limited
Grant/Research Support: Akcea Therapeutics, Inc.; Alexion Pharmaceuticals, Inc.; argenX; AstraZeneca; CSL; Grifols; Immunovant, Inc.; Ionis Pharmaceuticals; Johnson & Johnson Services, Inc.; Momenta; Octapharma USA, Inc.; Takeda Pharmaceutical Company Limited; UCB S.A.
|Carolina Barnett-Tapia, MD, PhD
|Consultant/Advisor: Alexion Pharmaceuticals, Inc.; argenX; Janssen Global Services, LLC; Sanofi; UCB S.A.|
Planners and Peer Reviewers
Timothy Hayes, MD, PhD; Kim Cheramie, MSN, RN-BC; Nicole McMenamin and Chelsey Simonds hereby state that they or their spouse/life partner do not have any relevant financial relationships to products or devices with any commercial interests related to the content of this activity of any amount during the past 12 months.
In support of improving patient care, AcademicCME is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
Credit Designation Statements
AcademicCME designates this enduring material for a maximum of 1.0 AMA PRA Category 1 CreditTM.
Clinicians should claim only the credit commensurate with the extent of their participation in the activity.
This activity has been supported by an independent educational grant from argenX.
Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. AcademicCME and argenX do not recommend the use of any agent outside of the labeled indications.
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
Method of Participation
In order to claim credit, participants must complete the following:
- Read the learning objectives, accreditation information and faculty disclosures at the beginning of this activity.
- Complete the Pre-Activity Questions
- Read or Review the activity content.
- Complete the Post-Activity Test Questions and Evaluation.
- Learners who receive a grade of 50% or better on the Post-Activity Test Questions and complete the Evaluation will receive appropriate credit as indicated (CME, CNE, and/or CPE credit).
- CME and CNE credit will be issued appropriate certificate of completion.
- Others may request a “certificate of completion”.
- Learners should claim only the credit commensurate with the extent of their participation in the activity.
CE Inquiries/Special Needs
For all CE inquiries or special needs, please contact [email protected].